title: AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.
abstract: In the 1940s Charles Huggins reported remarkable palliative benefits following surgical castration in men with advanced prostate cancer, and since then the androgen receptor (AR) has remained the main therapeutic target in this disease. Over the past couple of decades, our understanding of AR-signaling biology has dramatically improved, and it has become apparent that the AR can modulate a number of other well-described oncogenic signaling pathways. Not surprisingly, mounting preclinical and epidemiologic data now supports a role for AR-signaling in promoting the growth and progression of several cancers other than prostate, and early phase clinical trials have documented preliminary signs of efficacy when AR-signaling inhibitors are used in several of these malignancies. In this article, we provide an overview of the evidence supporting the use of AR-directed therapies in prostate as well as other cancers, with an emphasis on the rationale for targeting AR-signaling across tumor types.
authors.affiliation: Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA. schweize@u.washington.edu.|Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. schweize@u.washington.edu.
authors.forename: Michael T
authors.initials: MT
authors.lastname: Schweizer
authors.affiliation: Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA. evanyu@u.washington.edu.|Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. evanyu@u.washington.edu.
authors.forename: Evan Y
authors.initials: EY
authors.lastname: Yu
keywords: androgen receptor; bladder cancer; breast cancer; endometrial cancer; hepatocellular cancer; ovarian cancer; pancreatic cancer; prostate cancer; renal cell carcinoma